Pliaglis Numbing Cream (15G) (Expiry March 2025)

Pliaglis is a prescription only medicine indicated in adults to produce local dermal anaesthesia on intact skin prior to dermatological procedures. Pliaglis contains the local anaesthetics lidocaine and tetracaine.

Mode of action:

Pliaglis provides local dermal anaesthesia when applied to intact skin by the release of lidocaine and tetracaine into the epidermal and dermal layers of the skin with the accumulation of lidocaine and tetracaine in the area of dermal pain receptors and nerve endings. Both lidocaine and tetracaine block sodium ion channels required for the initiation and conduction of impulses, resulting in local anaesthesia.

Contraindications:

• Hypersensitivity to lidocaine, tetracaine, other anaesthetics of the amide or ester type, to para-aminobenzoic acid (a known by-product of tetracaine metabolism), methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216) or to any of the other excipients listed for the product.
• Pliaglis should not be used on mucous membranes or on broken or irritated skin.

Special warnings and precautions for use:

• Contact with eyes should be avoided.
• Apply with a spatula; do not use your fingers.
• Any remaining peel residue should be carefully wiped with a compress after removing Pliaglis peel.
• Pliaglis should be used with caution in patients with hepatic, renal or cardiac impairment, and in subjects with increased sensitivity to systemic circulatory effects of lidocaine and tetracaine, such as the acutely ill or debilitated.
• Refer to ‘Summary of Product Characteristics’ for a complete list of ‘Special warnings and precautions for use.

Store in refrigerator 2-8 C

EMC: https://www.medicines.org.uk/emc/product/14863/smpc#about-medicine

Patient Information Leaflet: https://www.medicines.org.uk/emc/files/pil.14863.pdf